News Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,512 ^JPY	+1.41%		+4.13%	+7.65%

Mar. 26	Santen Pharmaceutical to Cancel 12 Million Treasury Shares	MT
Mar. 25	Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL	Apr. 17	PU
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park	Apr. 16	PU
Final dividend	Mar. 27	FA
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis	Mar. 26	PU
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	Mar. 25	MT
Santen Pharmaceutical : Announces Change of Representative Director of the Board	Mar. 25	PU
Santen Pharmaceutical : Announces Cancellation of Treasury Shares	Mar. 25	PU
Santen Pharmaceutical : Announces Completion of Share Buyback	Mar. 25	PU
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	Mar. 25	CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	Mar. 25	CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	Mar. 21	CI
Santen Pharmaceutical : Announces Status of Share Buyback	Mar. 01	PU
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	Feb. 08	MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy	Jan. 29	MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	Jan. 07	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	Jan. 05	CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	Dec. 04	MT
Santen Pharmaceutical : Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension	Nov. 16	PU
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	Nov. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Summary

Filters